Compare HTBK & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTBK | CMPS |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 739.7M | 724.5M |
| IPO Year | 1998 | 2020 |
| Metric | HTBK | CMPS |
|---|---|---|
| Price | $13.45 | $9.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $12.88 | ★ $26.57 |
| AVG Volume (30 Days) | 682.5K | ★ 2.1M |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $3,688,000.00 | N/A |
| Revenue This Year | $7.80 | N/A |
| Revenue Next Year | $5.51 | N/A |
| P/E Ratio | $17.24 | ★ N/A |
| Revenue Growth | ★ 3.57 | N/A |
| 52 Week Low | $8.74 | $2.25 |
| 52 Week High | $13.83 | $8.90 |
| Indicator | HTBK | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 64.54 | 81.17 |
| Support Level | $11.85 | $5.95 |
| Resistance Level | $13.65 | N/A |
| Average True Range (ATR) | 0.31 | 0.40 |
| MACD | 0.07 | 0.36 |
| Stochastic Oscillator | 81.90 | 84.89 |
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. Majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.